Anebulo Pharmaceuticals, Inc.
ANEB
$2.30
-$0.01-0.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.04% | 36.91% | -19.45% | -13.84% | -18.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.90% | 13.70% | -6.24% | -5.17% | -46.26% |
| Operating Income | -73.90% | -13.70% | 6.24% | 5.17% | 46.26% |
| Income Before Tax | -58.87% | -1.37% | 9.36% | 11.29% | 45.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.87% | -1.37% | 9.36% | 11.29% | 45.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.87% | -1.37% | 9.36% | 11.29% | 45.90% |
| EBIT | -73.90% | -13.70% | 6.24% | 5.17% | 46.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.19% | 36.05% | 14.80% | 12.29% | 46.51% |
| Normalized Basic EPS | -0.31% | 36.09% | 14.72% | 12.40% | 46.55% |
| EPS Diluted | -0.19% | 36.05% | 14.80% | 12.29% | 46.51% |
| Normalized Diluted EPS | -0.31% | 36.09% | 14.72% | 12.40% | 46.55% |
| Average Basic Shares Outstanding | 58.43% | 58.43% | 6.30% | 1.17% | 1.17% |
| Average Diluted Shares Outstanding | 58.43% | 58.43% | 6.30% | 1.17% | 1.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |